Cost–utility analyses of drug therapies in breast cancer: a systematic review
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost–utility analyses of drug therapies in breast cancer: a systematic review
Authors
Keywords
Chemotherapy, Cost–utility analysis, Gene expression profiling, HER2 testing, Hormonotherapy, Quality-adjusted life year, Targeted therapy
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 159, Issue 3, Pages 407-424
Publisher
Springer Nature
Online
2016-08-30
DOI
10.1007/s10549-016-3924-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer
- (2015) Vakaramoko Diaby et al. BREAST CANCER RESEARCH AND TREATMENT
- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2015) Catherine Van Poznak et al. JOURNAL OF CLINICAL ONCOLOGY
- Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan
- (2014) Hideko Yamauchi et al. BMC HEALTH SERVICES RESEARCH
- Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer
- (2014) Aysegul Erman et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
- (2014) Vakaramoko Diaby et al. BREAST CANCER RESEARCH AND TREATMENT
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Sharon H. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Ann H. Partridge et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
- (2014) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic profile of breast cancer: cost–effectiveness analysis from the Spanish National Healthcare System perspective
- (2014) Miguel Ángel Seguí et al. Expert Review of Pharmacoeconomics & Outcomes Research
- TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES
- (2014) I. Van Vlaenderen et al. ACTA CLINICA BELGICA
- Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
- (2014) C. L. Attard et al. JOURNAL OF MEDICAL ECONOMICS
- Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer
- (2013) David Candon et al. ACTA ONCOLOGICA
- Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer
- (2013) Tamer Refaat et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2-positivo en Colombia
- (2013) Jefferson Antonio Buendía et al. Biomedica
- Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses
- (2013) Roman Rouzier et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer
- (2013) Thomas E. Delea et al. Breast Care
- A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK
- (2013) S Holt et al. BRITISH JOURNAL OF CANCER
- The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study
- (2013) C McCowan et al. BRITISH JOURNAL OF CANCER
- Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status
- (2013) Louis P. Garrison et al. CANCER
- Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer
- (2013) Kouta Ito et al. CANCER
- Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom
- (2013) Romita Das et al. CLINICAL THERAPEUTICS
- Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor–positive metastatic breast cancer in Canada
- (2013) T.E. Delea et al. Current Oncology
- A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer
- (2013) J.A. Davidson et al. EUROPEAN JOURNAL OF CANCER
- Prospective cost-effectiveness analysis of genomic profiling in breast cancer
- (2013) V.P. Retèl et al. EUROPEAN JOURNAL OF CANCER
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Economic burden of cancer across the European Union: a population-based cost analysis
- (2013) Ramon Luengo-Fernandez et al. LANCET ONCOLOGY
- Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer
- (2013) Malek B. Hannouf et al. PHARMACOECONOMICS
- The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance
- (2013) Gerardus W. J. Frederix et al. PHARMACOECONOMICS
- A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer
- (2013) Ava A. John-Baptiste et al. PLoS One
- Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer
- (2013) Mike Paulden et al. VALUE IN HEALTH
- The Cloudy Crystal Ball of Cost-Effectiveness Studies
- (2013) Gerardus W.J. Frederix et al. VALUE IN HEALTH
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
- (2013) Don Husereau et al. VALUE IN HEALTH
- The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence
- (2013) Mo Yang et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Cost–utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain
- (2013) Emilio Alba et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK
- (2013) Samantha Humphreys et al. Cancer Management and Research
- Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
- (2012) Tsui Fen Cheng et al. BMC CANCER
- Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer
- (2012) Malek B Hannouf et al. BMC CANCER
- Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan
- (2012) Masahide Kondo et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
- (2012) Nathan W. D. Lamond et al. BREAST CANCER RESEARCH AND TREATMENT
- A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer
- (2012) Gilberto Lopes et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost effectiveness of gene expression profiling for early stage breast cancer
- (2012) Mo Yang et al. CANCER
- Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer
- (2012) Sonya J. Snedecor et al. CLINICAL THERAPEUTICS
- Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
- (2012) Shelby D. Reed et al. GENETICS IN MEDICINE
- COST-UTILITY ANALYSIS OF ADJUVANT THERAPIES FOR BREAST CANCER IN IRAN
- (2012) Peivand Bastani et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Cost Effectiveness of Fracture Prevention in Postmenopausal Women Who Receive Aromatase Inhibitors for Early Breast Cancer
- (2012) Kouta Ito et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer
- (2012) L. Hedden et al. ONCOLOGIST
- Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6
- (2012) Andrew H. Briggs et al. VALUE IN HEALTH
- Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting
- (2012) J. U. Blohmer et al. JOURNAL OF MEDICAL ECONOMICS
- Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial
- (2011) Timo T. Purmonen et al. ACTA ONCOLOGICA
- Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer
- (2011) Stefan Glück et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
- (2011) Alberto J. Montero et al. BREAST CANCER RESEARCH AND TREATMENT
- Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance
- (2011) Valesca P. Retèl et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System
- (2011) Michael P. Lux et al. Breast Care
- The economic burden of metastatic breast cancer: A systematic review of literature from developed countries
- (2011) Talia S. Foster et al. CANCER TREATMENT REVIEWS
- A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735
- (2011) L. Bernard et al. Current Oncology
- The cost–utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer
- (2011) T. Younis et al. Current Oncology
- The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses
- (2011) H.E. Campbell et al. EUROPEAN JOURNAL OF CANCER
- Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast Cancer
- (2011) Peter S. Hall et al. JNCI-Journal of the National Cancer Institute
- Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer
- (2011) Peter S. Hall et al. PHARMACOECONOMICS
- Cost-Effectiveness of Granulocyte Colony–Stimulating Factor Prophylaxis for Febrile Neutropenia in Breast Cancer in the United Kingdom
- (2011) Sophie Whyte et al. VALUE IN HEALTH
- Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes
- (2011) Gerardus W.J. Frederix et al. VALUE IN HEALTH
- Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy
- (2011) James A Lee et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Trastuzumab beyond progression: a cost-utility analysis
- (2010) K. W. Matter-Walstra et al. ANNALS OF ONCOLOGY
- Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)
- (2010) Masahide Kondo et al. BREAST CANCER RESEARCH AND TREATMENT
- Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies
- (2010) Patricia R. Blank et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany
- (2010) Sebastian Braun et al. Breast Care
- Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain
- (2010) Carmen Frías et al. Clinical & Translational Oncology
- Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women With Hormone-Responsive Early Breast Cancer
- (2010) Thomas E. Delea et al. Clinical Breast Cancer
- Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan
- (2010) Hiroshi Ishiguro et al. CLINICAL THERAPEUTICS
- Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer
- (2010) Michael Lipsitz et al. CURRENT MEDICAL RESEARCH AND OPINION
- Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
- (2010) Valesca P. Retèl et al. EUROPEAN JOURNAL OF CANCER
- Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context
- (2010) Hye-Jae Lee et al. Journal of Breast Cancer
- When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in Oncology
- (2010) Dan Greenberg et al. JNCI-Journal of the National Cancer Institute
- Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer
- (2010) D. T. Tsoi et al. ONCOLOGIST
- Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System
- (2010) Michael P. Lux et al. ONKOLOGIE
- Results of the Zometa® Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study
- (2010) Michael P. Lux et al. ONKOLOGIE
- Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer
- (2010) Patricia R. Blank et al. PHARMACOECONOMICS
- Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization
- (2010) Shmuel H. Klang et al. VALUE IN HEALTH
- High-Dose Chemotherapy for Patients With High-Risk Breast Cancer
- (2009) Patricia Marino et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study
- (2009) P. Marino et al. ANNALS OF ONCOLOGY
- Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK
- (2009) J. F. S. Logman et al. ANNALS OF ONCOLOGY
- Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review
- (2009) Agnes LF Chan et al. ANNALS OF PHARMACOTHERAPY
- Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model
- (2009) Michael Patrick Lux et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients
- (2009) Kathryn A. Phillips et al. CANCER
- Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer
- (2009) Quang A. Le et al. CANCER
- Cost-effectiveness analysis of docetaxel (Taxotere®) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer
- (2009) Miguel Martín-Jiménez et al. Clinical & Translational Oncology
- Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states
- (2009) Gary H. Lyman et al. CLINICAL THERAPEUTICS
- Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation
- (2009) Konstantin J. Dedes et al. EUROPEAN JOURNAL OF CANCER
- Economic evaluation of docetaxel for breast cancer
- (2009) Zarnie Lwin et al. EXPERT OPINION ON PHARMACOTHERAPY
- AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews
- (2009) Beverley J. Shea et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
- (2009) Shelby D. Reed et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK
- (2009) Ágnes Benedict et al. PHARMACOECONOMICS
- Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective
- (2009) Peng Liubao et al. PHARMACOECONOMICS
- The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial
- (2009) Chris Skedgel et al. VALUE IN HEALTH
- An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
- (2009) Wen Chen et al. VALUE IN HEALTH
- Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer
- (2008) Mathias Lidgren et al. ACTA ONCOLOGICA
- Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial
- (2008) N. Maniadakis et al. ANNALS OF ONCOLOGY
- Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
- (2008) Sang Gyu Lee et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
- (2008) Heather-Jane Au et al. BREAST CANCER RESEARCH AND TREATMENT
- Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
- (2008) D A Cameron et al. BRITISH JOURNAL OF CANCER
- Comparison of three instruments assessing the quality of economic evaluations: A practical exercise on economic evaluations of the surgical treatment of obesity
- (2008) Sophie Gerkens et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis
- (2008) Sorrel E. Wolowacz et al. JOURNAL OF CLINICAL ONCOLOGY
- Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer
- (2008) Lieven Annemans PHARMACOECONOMICS
- Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy
- (2008) Scott D. Ramsey et al. VALUE IN HEALTH
- Is trastuzumab a cost-effective treatment for breast cancer?
- (2008) Tallal Younis et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer
- (2008) George Dranitsaris et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now